{"groups":[{"description":"Participants with MM received AMG 176 Dose A BIW. AMG 176 was administered as an intravenous (IV) infusion in a 4-week cycle.","id":"FG000","title":"Part 1A Cohort 1 (MM): AMG 176 Dose A Twice Weekly (BIW)"},{"description":"Participants with MM received AMG 176 Dose B IV BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"FG001","title":"Part 1A Cohort 2 (MM): AMG 176 Dose B BIW"},{"description":"Participants with MM received AMG 176 Dose C BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"FG002","title":"Part 1A Cohort 3 (MM): AMG 176 Dose C BIW"},{"description":"Participants with MM received AMG 176 Dose D BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"FG003","title":"Part 1A Cohort 4 (MM): AMG 176 Dose D BIW"},{"description":"Participants with MM received AMG 176 Dose E BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"FG004","title":"Part 1A Cohort 5 (MM): AMG 176 Dose E BIW"},{"description":"Participants with MM received AMG 176 Dose G BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"FG005","title":"Part 1A Cohort 6 (MM): AMG 176 Dose G BIW"},{"description":"Participants with MM received AMG 176 Dose E in cycle 1 week 1, then received Dose F BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"FG006","title":"Part 1A Cohort 7 (MM): AMG 176 Dose E Then Dose F BIW"},{"description":"Participants with MM received AMG 176 Dose E in cycle 1 week 1, then received Dose G BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"FG007","title":"Part 1A Cohort 8 (MM): AMG 176 Dose E Then Dose G BIW"},{"description":"Participants with MM received AMG 176 Dose E in cycle 1 week 1, then received Dose H BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"FG008","title":"Part 1A Cohort 9 (MM): AMG 176 Dose E Then Dose H BIW"},{"description":"Participants with MM received AMG 176 Dose E in cycle 1 week 1, then received Dose I BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"FG009","title":"Part 1A Cohort 10 (MM): AMG 176 Dose E Then Dose I BIW"},{"description":"Participants with MM received AMG 176 Dose E in cycle 1 week 1, then received Dose F QW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"FG010","title":"Part 1B Cohort 1 (MM): AMG 176 Dose E Then Dose F Once Weekly (QW)"},{"description":"Participants with MM received AMG 176 Dose E in cycle 1 week 1, then received Dose G QW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"FG011","title":"Part 1B Cohort 2 (MM): AMG 176 Dose E Then Dose G QW"},{"description":"Participants with MM received AMG 176 Dose E in cycle 1 week 1, then received Dose H QW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"FG012","title":"Part 1B Cohort 3 (MM): AMG 176 Dose E Then Dose H QW"},{"description":"Participants with MM received AMG 176 Dose E in cycle 1 week 1, then received Dose I QW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"FG013","title":"Part 1B Cohort 4 (MM): AMG 176 Dose E Then Dose I QW"},{"description":"Participants with AML received AMG 176 Dose D BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"FG014","title":"Part 3A Cohort 1 (AML): AMG 176 Dose D BIW"},{"description":"Participants with AML received AMG 176 Dose E BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"FG015","title":"Part 3A Cohort 2 (AML): AMG 176 Dose E BIW"},{"description":"Participants with AML received AMG 176 Dose E in cycle 1 week 1, then received Dose F BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"FG016","title":"Part 3A Cohort 3 (AML): AMG 176 Dose E Then Dose F BIW"},{"description":"Japanese participants with AML received AMG 176 Dose E in cycle 1 week 1, then received Dose F QW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"FG017","title":"Part 3A Cohort 4 (Japanese Participants With AML): AMG 176 Dose E Then Dose F QW"},{"description":"Participants with AML received AMG 176 Dose E QW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"FG018","title":"Part 3B Cohort 1 (AML): AMG 176 Dose E QW"},{"description":"Participants with AML received AMG 176 Dose E in cycle 1 week 1, then received Dose F QW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"FG019","title":"Part 3B Cohort 2 (AML): AMG 176 Dose E Then Dose F QW"},{"description":"Participants with AML received AMG 176 Dose E in cycle 1 week 1, then received Dose G QW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"FG020","title":"Part 3B Cohort 3 (AML): AMG 176 Dose E Then Dose G QW"},{"description":"Japanese participants with AML received AMG 176 Dose E QW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"FG021","title":"Part 3C Cohort 1 (Japanese Participants With AML): AMG 176 Dose E QW"},{"description":"Participants with AML received AMG 176 Dose D QW. AMG 176 was administered as an IV infusion in a 4-week cycle. They also received 200 mg itraconazole once daily (QD) for 7 days in week 1.","id":"FG022","title":"Part 3D Cohort 1 (AML): AMG 176 Dose D QW + Itraconazole"},{"description":"Participants with AML received AMG 176 Dose D QW. AMG 176 was administered as an IV infusion in a 4-week cycle. They also received 75 mg/m\\^2 azacitidine subcutaneously (SC) or IV QD for 7 days in week 1.","id":"FG023","title":"Part 4 Cohort 1 (AML): AMG 176 Dose D QW + Azacitidine"},{"description":"Participants with AML received AMG 176 Dose E QW. AMG 176 was administered as an IV infusion in a 4-week cycle. They also received 75 mg/m\\^2 azacitidine SC or IV QD for 7 days in week 1.","id":"FG024","title":"Part 4 Cohort 2 (AML): AMG 176 Dose E QW + Azacitidine"},{"description":"Participants with AML received AMG 176 Dose E in cycle 1 week 1, then received Dose F QW. AMG 176 was administered as an IV infusion in a 4-week cycle. They also received 75 mg/m\\^2 azacitidine SC or IV QD for 7 days in week 1.","id":"FG025","title":"Part 4 Cohort 3 (AML): AMG 176 Dose E Then Dose F QW + Azacitidine"},{"description":"Participants with AML received AMG 176 Dose E in cycle 1 week 1, then received Dose G QW. AMG 176 was administered as an IV infusion in a 4-week cycle. They also received 75 mg/m\\^2 azacitidine SC or IV QD for the first 7 days of the 4-week cycle.","id":"FG026","title":"Part 4 Cohort 4 (AML): AMG 176 Dose E Then Dose G QW + Azacitidine"},{"description":"Participants with AML received AMG 176 Dose E BIW. AMG 176 was administered as an IV infusion in a 4-week cycle. They also received 75 mg/m\\^2 azacitidine SC or IV QD for the first 7 days of the 4-week cycle.","id":"FG027","title":"Part 4 Cohort 5A (AML): AMG 176 Dose E BIW + Azacitidine"},{"description":"Participants with AML received AMG 176 Dose E in cycle 1 week 1, then received Dose G BIW. AMG 176 was administered as an IV infusion in a 4-week cycle. They also received 75 mg/m\\^2 azacitidine SC or IV QD for the first 7 days of the 4-week cycle.","id":"FG028","title":"Part 4 Cohort 5B (AML): AMG 176 Dose E the Dose G BIW + Azacitidine"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"1"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"2"},{"groupId":"FG014","numSubjects":"1"},{"groupId":"FG015","numSubjects":"0"},{"groupId":"FG016","numSubjects":"1"},{"groupId":"FG017","numSubjects":"0"},{"groupId":"FG018","numSubjects":"0"},{"groupId":"FG019","numSubjects":"0"},{"groupId":"FG020","numSubjects":"0"},{"groupId":"FG021","numSubjects":"0"},{"groupId":"FG022","numSubjects":"0"},{"groupId":"FG023","numSubjects":"0"},{"groupId":"FG024","numSubjects":"0"},{"groupId":"FG025","numSubjects":"0"},{"groupId":"FG026","numSubjects":"2"},{"groupId":"FG027","numSubjects":"0"},{"groupId":"FG028","numSubjects":"0"}],"type":"Sponsor decision"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"1"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"1"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"1"},{"groupId":"FG014","numSubjects":"1"},{"groupId":"FG015","numSubjects":"0"},{"groupId":"FG016","numSubjects":"2"},{"groupId":"FG017","numSubjects":"0"},{"groupId":"FG018","numSubjects":"0"},{"groupId":"FG019","numSubjects":"0"},{"groupId":"FG020","numSubjects":"0"},{"groupId":"FG021","numSubjects":"0"},{"groupId":"FG022","numSubjects":"3"},{"groupId":"FG023","numSubjects":"0"},{"groupId":"FG024","numSubjects":"1"},{"groupId":"FG025","numSubjects":"0"},{"groupId":"FG026","numSubjects":"1"},{"groupId":"FG027","numSubjects":"3"},{"groupId":"FG028","numSubjects":"4"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"1"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"1"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"1"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"0"},{"groupId":"FG015","numSubjects":"2"},{"groupId":"FG016","numSubjects":"0"},{"groupId":"FG017","numSubjects":"0"},{"groupId":"FG018","numSubjects":"4"},{"groupId":"FG019","numSubjects":"3"},{"groupId":"FG020","numSubjects":"3"},{"groupId":"FG021","numSubjects":"3"},{"groupId":"FG022","numSubjects":"7"},{"groupId":"FG023","numSubjects":"5"},{"groupId":"FG024","numSubjects":"3"},{"groupId":"FG025","numSubjects":"4"},{"groupId":"FG026","numSubjects":"7"},{"groupId":"FG027","numSubjects":"6"},{"groupId":"FG028","numSubjects":"9"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"1"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"0"},{"groupId":"FG015","numSubjects":"0"},{"groupId":"FG016","numSubjects":"0"},{"groupId":"FG017","numSubjects":"0"},{"groupId":"FG018","numSubjects":"0"},{"groupId":"FG019","numSubjects":"0"},{"groupId":"FG020","numSubjects":"0"},{"groupId":"FG021","numSubjects":"0"},{"groupId":"FG022","numSubjects":"0"},{"groupId":"FG023","numSubjects":"0"},{"groupId":"FG024","numSubjects":"0"},{"groupId":"FG025","numSubjects":"0"},{"groupId":"FG026","numSubjects":"1"},{"groupId":"FG027","numSubjects":"0"},{"groupId":"FG028","numSubjects":"0"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"0"},{"groupId":"FG015","numSubjects":"0"},{"groupId":"FG016","numSubjects":"0"},{"groupId":"FG017","numSubjects":"0"},{"groupId":"FG018","numSubjects":"0"},{"groupId":"FG019","numSubjects":"0"},{"groupId":"FG020","numSubjects":"0"},{"groupId":"FG021","numSubjects":"0"},{"groupId":"FG022","numSubjects":"0"},{"groupId":"FG023","numSubjects":"0"},{"groupId":"FG024","numSubjects":"0"},{"groupId":"FG025","numSubjects":"0"},{"groupId":"FG026","numSubjects":"1"},{"groupId":"FG027","numSubjects":"0"},{"groupId":"FG028","numSubjects":"0"}],"type":"Other"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"4"},{"groupId":"FG003","numSubjects":"3"},{"groupId":"FG004","numSubjects":"3"},{"groupId":"FG005","numSubjects":"2"},{"groupId":"FG006","numSubjects":"4"},{"groupId":"FG007","numSubjects":"4"},{"groupId":"FG008","numSubjects":"5"},{"groupId":"FG009","numSubjects":"5"},{"groupId":"FG010","numSubjects":"3"},{"groupId":"FG011","numSubjects":"3"},{"groupId":"FG012","numSubjects":"3"},{"groupId":"FG013","numSubjects":"3"},{"groupId":"FG014","numSubjects":"6"},{"groupId":"FG015","numSubjects":"5"},{"groupId":"FG016","numSubjects":"5"},{"groupId":"FG017","numSubjects":"2"},{"groupId":"FG018","numSubjects":"4"},{"groupId":"FG019","numSubjects":"3"},{"groupId":"FG020","numSubjects":"4"},{"groupId":"FG021","numSubjects":"4"},{"groupId":"FG022","numSubjects":"10"},{"groupId":"FG023","numSubjects":"5"},{"groupId":"FG024","numSubjects":"5"},{"groupId":"FG025","numSubjects":"4"},{"groupId":"FG026","numSubjects":"13"},{"groupId":"FG027","numSubjects":"10"},{"groupId":"FG028","numSubjects":"13"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"4"},{"groupId":"FG003","numSubjects":"3"},{"groupId":"FG004","numSubjects":"3"},{"groupId":"FG005","numSubjects":"2"},{"groupId":"FG006","numSubjects":"4"},{"groupId":"FG007","numSubjects":"4"},{"groupId":"FG008","numSubjects":"5"},{"groupId":"FG009","numSubjects":"5"},{"groupId":"FG010","numSubjects":"3"},{"groupId":"FG011","numSubjects":"3"},{"groupId":"FG012","numSubjects":"3"},{"groupId":"FG013","numSubjects":"3"},{"groupId":"FG014","numSubjects":"5"},{"groupId":"FG015","numSubjects":"5"},{"groupId":"FG016","numSubjects":"5"},{"groupId":"FG017","numSubjects":"2"},{"groupId":"FG018","numSubjects":"4"},{"groupId":"FG019","numSubjects":"3"},{"groupId":"FG020","numSubjects":"4"},{"groupId":"FG021","numSubjects":"4"},{"groupId":"FG022","numSubjects":"10"},{"groupId":"FG023","numSubjects":"5"},{"groupId":"FG024","numSubjects":"4"},{"groupId":"FG025","numSubjects":"4"},{"groupId":"FG026","numSubjects":"13"},{"groupId":"FG027","numSubjects":"10"},{"groupId":"FG028","numSubjects":"13"}],"type":"Received AMG 176"},{"achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"3"},{"groupId":"FG004","numSubjects":"3"},{"groupId":"FG005","numSubjects":"1"},{"groupId":"FG006","numSubjects":"4"},{"groupId":"FG007","numSubjects":"4"},{"groupId":"FG008","numSubjects":"4"},{"groupId":"FG009","numSubjects":"3"},{"groupId":"FG010","numSubjects":"3"},{"groupId":"FG011","numSubjects":"2"},{"groupId":"FG012","numSubjects":"1"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"4"},{"groupId":"FG015","numSubjects":"3"},{"groupId":"FG016","numSubjects":"2"},{"groupId":"FG017","numSubjects":"2"},{"groupId":"FG018","numSubjects":"0"},{"groupId":"FG019","numSubjects":"0"},{"groupId":"FG020","numSubjects":"1"},{"groupId":"FG021","numSubjects":"1"},{"groupId":"FG022","numSubjects":"0"},{"groupId":"FG023","numSubjects":"0"},{"groupId":"FG024","numSubjects":"1"},{"groupId":"FG025","numSubjects":"0"},{"groupId":"FG026","numSubjects":"1"},{"groupId":"FG027","numSubjects":"1"},{"groupId":"FG028","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"1"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"1"},{"groupId":"FG009","numSubjects":"2"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"1"},{"groupId":"FG012","numSubjects":"2"},{"groupId":"FG013","numSubjects":"3"},{"groupId":"FG014","numSubjects":"2"},{"groupId":"FG015","numSubjects":"2"},{"groupId":"FG016","numSubjects":"3"},{"groupId":"FG017","numSubjects":"0"},{"groupId":"FG018","numSubjects":"4"},{"groupId":"FG019","numSubjects":"3"},{"groupId":"FG020","numSubjects":"3"},{"groupId":"FG021","numSubjects":"3"},{"groupId":"FG022","numSubjects":"10"},{"groupId":"FG023","numSubjects":"5"},{"groupId":"FG024","numSubjects":"4"},{"groupId":"FG025","numSubjects":"4"},{"groupId":"FG026","numSubjects":"12"},{"groupId":"FG027","numSubjects":"9"},{"groupId":"FG028","numSubjects":"13"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Participants with multiple myeloma (MM) or with acute myeloid leukemia (AML) were enrolled into 29 cohorts. Dosing of AMG 176 was from Dose A (lowest) to Dose I (highest).","recruitmentDetails":"Participants were enrolled at 21 study centers in the United States, Canada, Australia, Germany, and Japan, and participated from June 2016 to May 2024. The study was conducted in multiple parts and Part 5 did not enroll any participants due to early termination of the study. Part 2 was removed during a protocol amendment."}